Dr. Jeffrey Zonder

Pleased to part of the #ICE2025 group that will cycle across Iceland later this summer, raising $$ & awareness for #myeloma research. How can u support a great cause? Click the link. Every dollar goes to cancer research! fundraise.myeloma.org/fundraiser/5... @imfmyeloma.bsky.social

It’s time! I’m raising funds to support #myeloma research as part of the #ICE2025 biking team headed to Iceland later this summer. Biking? Me? No mountains? YEP! and 100% of the $$$ raised goes to support groundbreaking cancer research. Support by clicking here: fundraise.myeloma.org/fundraiser/5...

Amyloid can be nearly invisible on fat pad biopsies without congo red stain. Note the non-specific whitish collagen signal when polarized compared to yellow-green amyloid colors. Texas red IF filter can be very helpful to differentiate background from real congo red staining. #pathsky #nephsky

Poster #ASH24: better improvements in pain & fatigue at D+90 post #mmsm CAR in underrepresented minorities. However, also notice 29% of minorities with worsening fatigue; subgroup analysis to better understand predictors of better vs worse fatigue. #MajorPROsASH

Pat LoRusso @yalecancer.bsky.social elegantly reviews what we need for dose optimization in drug development #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social

Kaplan–Meier estimates of progression-free survival in the intention-to-treat population.

Presented at #ASH24:

Among patients with smoldering multiple myeloma at a high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring. Full AQUILA trial results: nej.md/3Zh3pOJ

#MedSky

Impressive results for Anito-Cel new BCMA-targeted CART for #myeloma after median 4 prior lines of Rx. Proud that the #Karmanos Cancer Institute’s Dr Abhinav Deol was a co-investigator. This CART now in Phase 3 trial

Yup worked in the app! Thanks again for sending! BIG help!

BCMA/GPRC5D-dual targeting CART for relapsed #myeloma. The usual CART toxicity, decent response rates, and somehow no skin and/or nail changes. #ASH24

Thanks!!!!!! Super helpful!

BCMA CART for smoldering #myeloma: high MRD(-) rates and no neurological DLTs (including late Parkinsonism) to date. Enjoy the honeymoon….and the IVIg? #ASH24

Predictably, after 5y of F/U the OS of cardiac stage 1-3a AL #amyloidosis is improved by adding Dara to CyBorD. This re-affirms prior landmark analyses showing depth of initial FLC response predicts subsequent survival. #ASH24

GLS >(-9) independently predictive of survival when added to criteria for AL stage 3b cardiac #amyloidosis:

3b + bad GLS = 3c

In practice, may eventually identify pts who could particularly benefit from anti-fibril therapy

Links didn’t work ☹️

MRD negativity (with 10^(-5) threshold) in AL #amyloidosis doesn’t seem to predict overall survival or organ response….just TTNT (and median TTP?). Results a bit underwhelming, though the 300+ patient analysis was an impressive effort #ASH24

I’m not sure I’m done w X, but for now, I’m pretty “done” with X. Keeping it focused on myeloma, amyloidosis, hematology, and science here. Maybe comics, art, backpacking, and running. No politics. Will not abide random aggressive trolling. #mmsm #myeloma #amyloidosis

Any #myeloma or #mmsm or #nephrology or #hematology or #ASH24 “starter packs” of accounts to follow out there? Just signed up and looking for my peeps.